No Data
Arvinas (NASDAQ:ARVN Investor Three-year Losses Grow to 68% as the Stock Sheds US$99m This Past Week
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But the long term shareholders of Arvinas, Inc. (NASDAQ:ARVN) have had an unfortunat
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today an
Express News | Arvinas- Due to Hsr Termination & Satisfaction of Closing Conditions of License Agreement, Asset Agreement, Novartis Pharma AG to Pay Co $150.0 Mln
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 c
Form 144 | Arvinas(ARVN.US) Insider Proposes to Sell 1.65 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 20, $Arvinas(ARVN.US)$ Insider Sean Cassidy intends to sell 50,000 shares of its common stock on May 20, with a total market value of approximately $1.65 million. Sean Ca